Related Experiment Video

Updated: May 17, 2026

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
09:08

Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer

Published on: January 12, 2020

A novel anticancer therapy that simultaneously targets aberrant p53 and Notch activities in tumors

Yuting Yao1, Li Wang, He Zhang

  • 1Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, People's Republic of China.

Plos One
|October 17, 2012
PubMed

Insights

Combining H101 oncolytic adenovirus with Notch1-siRNA offers a novel cancer therapy. This dual approach targets cancer stem cells and enhances viral replication, inhibiting tumor growth in p53-inactive cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Gene Therapy

Background:

  • Notch signaling is crucial for cancer stem cell self-renewal and tumor progression.
  • H101 oncolytic adenovirus targets p53-inactive cancer cells but cannot eliminate cancer stem cells.

Purpose of the Study:

  • To evaluate a combined gene therapy strategy using H101 oncolytic adenovirus and Notch1-siRNA.
  • To determine the efficacy of this combination in inhibiting tumor formation and progression.

Main Methods:

  • Utilized HeLa-S3 tumor cells and nude mice xenograft models.
  • Administered a combination of H101 and Notch1-siRNA.
  • Assessed Notch pathway activity, apoptosis induction, tumor growth inhibition, and H101 replication.

Main Results:

  • The combined therapy effectively blocked the Notch pathway and induced apoptosis in p53-inactive HeLa-S3 tumor cells.
  • Combination treatment significantly inhibited tumor growth in xenograft models.
  • Notch1-siRNA enhanced H101 replication and oncolytic activity by increasing Hexon gene expression.

Conclusions:

  • The combination of H101 oncolytic adenovirus and Notch1-siRNA represents a feasible and potent novel anti-cancer therapy.
  • This strategy synergistically targets cancer stem cells and enhances oncolysis for p53-inactive tumors.

More Related Videos

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence04:56

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence

Published on: December 30, 2025

Yeast As a Chassis for Developing Functional Assays to Study Human P5314:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Notch Signaling Pathway03:14

Notch Signaling Pathway

The Notch signaling pathway is a major intracellular signaling pathway that is highly conserved over a broad spectrum of metazoan species. It stands unique from other intracellular signaling mechanisms in animals because notch protein itself acts as the receptor as well as the primary signaling molecule.
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not until 1985...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Role Of Notch Signalling In Intestinal Stem Cell Renewal01:12

Role Of Notch Signalling In Intestinal Stem Cell Renewal

Notch signaling was first discovered in Drosophila melanogaster, where it is involved in cell lineage differentiation. Notch signaling regulates the maintenance and differentiation of intestinal stem cells or ISCs by controlling the expression of atonal homolog 1 or Atoh1. Atoh1 directs cells to differentiate into secretory cells.
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.